|
1
|
Pavlidis N and Fizazi K: Carcinoma of
unknown primary (CUP). Crit Rev Oncol Hematol. 69:271–278. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pavlidis N, Briasoulis E, Hainsworth J and
Greco F: Diagnostic and therapeutic management of cancer of an
unknown primary. Eur J Cancer. 39:1990–2005. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Krementz ET, Cerise EJ, Foster DS and
Morgan L Jr: Metastases of undetermined source. Curr Pobl Cancer.
4:4–37. 1979.
|
|
4
|
Bosetti C, Rodríguez T, Chatenoud L,
Bertuccio P, Levi F, Negri E and La Vecchia C: Trends in cancer
mortality in Mexico, 1981–2007. Eur J Cancer Prev. 20:355–363.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pentheroukadis G, Briasoulis E and
Pavlidis N: Cancer of unknown primary site: Missing primary or
missing biology? Oncologist. 12:418–425. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sporn JR and Greenberg BR: Empirical
chemotherapy for adenocarcinoma of unknown primary site. Semin
Oncol. 20:261–267. 1993.PubMed/NCBI
|
|
7
|
Culine S: Prognostic factors in unknown
primary cancer. Semin Oncol. 36:60–64. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Abbruzzese JL, Abbruzzese MC, Hess KR,
Raber MN, Lenzi R and Frost P: Unknown primary carcinoma: Natural
history and prognostic factors in 657 consecutive patients. J Clin
Oncol. 12:1272–1280. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hess KR, Abbruzzese MC, Lenzi R, Raber MN
and Abbruzzese JL: Classification and regression tree analysis of
1,000 consecutive patients with unknown primary carcinoma. Clin
Cancer Res. 5:3403–3410. 1999.PubMed/NCBI
|
|
10
|
Lortholary A, Abadie-Lacourtoisie S,
Guérin O, Mege M, Rauglaudre GD and Gamelin E: Cancers of unknown
origin: 311 cases. Bull Cancer. 88:619–627. 2001.(In French).
PubMed/NCBI
|
|
11
|
Culine S, Kramar A, Saghatchian M, Bugat
R, Lesimple T, Lortholary A, Merrouche Y, Laplanche A and Fizazi K:
French Study Group on Carcinomas of Unknown Primary: Development
and validation of a prognostic model to predict the length of
survival in patients with carcinomas of an unknown primary site. J
Clin Oncol. 20:4679–4683. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Seve P, Ray-Coquard I, Trillet-Lenoir V,
Sawyer M, Hanson J, Broussolle C, Negrier S, Dumontet C and Mackey
JR: Low serum albumin levels and liver metastases are powerful
prognostic markers for survival in patients with carcinomas of
unknown primary site. Cancer. 107:2698–2705. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lenzi R, Abbruzzese J, Amato R, et al:
Cisplatin, 5-fluorouracil and follinic acid for the treatment of
carcinoma of unknown primary: A phase II study. Proc Am Soc Clin
Oncol. 10:3011991.
|
|
14
|
Farrugia DC, Norman AR, Nicolson MC, Gore
M, Bolodeoku ED, Webb A and Cunningham D: Unknown primary
carcinoma: Randomized studies are needed to identify optimal
treatments and their benefits. Eur J Cancer. 32A:2256–2261. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rigg A, Cunningham D, Gore M, Hill M,
O'Brien M, Nicolson M, Chang J, Watson M, Norman A, Hill A, Oates
J, et al: A phase I/II study of leucovorin, carboplatin and
5-fluorouracil (LCF) in patients with carcinoma of unknown primary
site or advanced oesophagogastric/pancreatic adenocarcinomas. Br J
Cancer. 75:101–105. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pavlidis N, Kosmidis P, Skarlos D,
Brissoulis E, Beer M, Theoharis D, Bafaloukos D, Maraveyas A and
Fountzilas G: Subsets of tumors responsive to cisplatin or
carboplatin combinatios in patients with carcinoma of unknown
primary site. A hellenic cooperative oncology group study. Ann
Oncol. 3:631–634. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Briasoulis E, Tsavaris N, Fountzilas G,
Athanasiadis A, Kosmidis P, Bafaloukos D, Skarlos D, Samantas E and
Pavlidis N: Combination regimen with carboplatin, epirubicin and
etoposide in metastatic carcinomas of unknown primary site: A
Hellenic Co-oncology group phase II study. Oncology. 55:426–430.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Warner E, Goel R, Chang J, Chow W, Verma
S, Dancey J, Franssen E, Dulude H, Girouard M, Correia J and
Gallant G: A mulicenter phase II study of carboplatin and prolonged
oral etoposide in the treatment of cancer of unknown primary site
(CUPS). Br J Cancer. 77:2376–2380. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Voog E, Merrouche Y, Trillet-Lenoir V,
Lasset C, Peaud PY, Rebattu P and Negrier S: Multicentric phase II
study of cisplatin and etoposide in patients with metastatic
carcinoma of unknown primary. Am J Clin Oncol. 23:614–616. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Macdonald AG, Nicolson MC, Samuel LM,
Hutcheon AW and Ahmed FY: A phase II study of mitomycin C,
cisplatin and continuous infusion 5-fluorouracil (MCF) in the
treatment of patients with carcinoma of unknown primary site. Br J
Cancer. 86:1238–1242. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Piga A, Gesuita R, Catalano V, Nortilli R,
Getto G, Cardillo F, Giorgi F, Riva N, Porfiri E, Montironi R, et
al: Identification of clinical prognostic factors in patients with
unknown primary tumors treated with a platinum-based combination.
Oncology. 69:135–144. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pittman KB, Olver IN, Koczwara B, Kotasek
D, Patterson WK, Keefe DM, Karapetis CS, Parnis FX, Moldovan S,
Yeend SJ, et al: Gemcitabine and carboplatin in carcinoma of
unknown primary site: A phase II Adelaide cancer trials and
education collaborative study. Br J Cancer. 95:1309–1313. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hainsworth JD, Erland JB, Kalman LA,
Schreeder MT and Greco FA: Carcinoma of unknown primary site:
Treatment with 1-h paclitaxel, carboplatin, and extended-schedule
etoposide. J Clin Oncol. 15:2385–2393. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Briasoulis E, Kalofonos H, Bafaloukos D,
Samantas E, Fountzilas G, Xiros N, Skarlos D, Christodoulou C,
Kosmidis P and Pavlidis N: Carboplatin plus paclitaxel in unknown
primary carcinoma: A phase II study. The Hellenic cooperative
oncology group study. J Clin Oncol. 18:3101–3117. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Greco FA, Burris HA III, Erland JB, Gray
JR, Kalman LA, Schreeder MT and Hainsworth JD: Carcinoma of unknown
primary site. Cancer. 89:2655–2660. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bouleuc C, Saghatchian M, Di Tullio L,
Louvet CH, Levy E, Di Palma M, et al: A multicenter phase II study
of docetaxel and cisplatin in the treatment of cancer of unknown
primary site. Proc Am Soc Clin Oncol. 137b:22982001.
|
|
27
|
Darby A, Richardson L, Nokes L, Harvey M,
Hassan A and Iveson T: Phase II study of single agent docetaxel in
carcinoma of unknown primary site. Proc Am Soc Clin Oncol.
100b:21512001.
|
|
28
|
Gothelf A, Daugaard G and Nelausen K:
Paclitaxel, cisplatin and gemcitabine in the treatment of unknown
primary tumours, a phase II study. ESMO. 25:882002.
|
|
29
|
Greco FA, Burris HA III, Litchy S, Barton
JH, Bradof JE, Richards P, Scullin DC Jr, Erland JB, Morrissey LH
and Hainsworth JD: Gemcitabine, carboplatin, and paclitaxel for
patients with carcinoma of unknown primary site: A Minnie pearl
cancer research network study. J Clin Oncol. 20:1651–1656. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Greco FA, Rodriguez GI, Shaffer DW,
Hermann R, Litchy S, Yardley DA, Burris HA III, Morrissey LH,
Erland JB and Hainsworth JD: Carcinoma of unknown primary site:
Sequential treatment with paclitaxel/carboplatin/etoposide and
gemcitabine/irinotecan: A Minnie pearl cancer research network
phase II trial. Oncologist. 9:644–652. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Park YH, Ryoo BY, Choi SJ, Yang SH and Kim
HT: A phase II study of paclitaxel plus cisplatin chemotherapy in
an unfavourable group of patients with cancer of unknown primary
site. Jpn J Clin Oncol. 34:681–685. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pouessel D, Culine S, Becht C, Ychou M,
Romieu G, Fabbro M, Cupissol D and Pinguet F: Gemcitabine and
docetaxel as front-line chemotherapy in patients with carcinoma of
an unknown primary site. Cancer. 100:1257–1261. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
El-Rayes BF, Shields AF, Zalupski M,
Heilbrum LK, Jain V, Terry D, Ferris AM and Philip PA: A phase II
study of carboplatin and paclitaxel in adenocarcinoma of unknown
primary. Am J Clin Oncol. 28:152–156. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hainsworth JD, Spigel DR, Litchy S and
Greco FA: Phase II trial of paclitaxel, carboplatin, and etoposide
in advanced poorly differentiated neuroendocrine carcinoma: A
Minnie pearl cancer research network study. J Clin Oncol.
24:3548–3554. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
van der Gaast A, Verweij J, Henzen-Logmans
SC, Rodenburg CJ and Stoter G: Carcinoma of unknown primary:
Identification of a treatable subset? Ann Oncol. 1:119–122. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hainsworth JD, Johnson DH and Greco FA:
The role of etoposide in the treatment of poorly differenciated
carcinoma of unknown primary site. Cancer. 67:(Suppl 1). S310–S314.
1991. View Article : Google Scholar
|
|
37
|
Khansur T, Allred C, Little D and Anand V:
Cisplatin and 5-fluorouracil for metastatic squamous cell carcinoma
from unknown primary. Cancer Invest. 13:263–266. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Greco FA, Vaughn WK and Hainsworth JD:
Advanced poorly differenciated carcinoma of unknown primary site:
Recognition of a treatable syndrome. Ann Intern Med. 104:547–553.
1986. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Falkson CI and Cohen GL: Mitomycin,
epirubicin and cisplatin versus mitomycin-C alone as therapy for
carcinoma ok unknown primary origin. Oncology. 55:116–121. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Guardiola E, Pivot X, Tchicknavorian X,
Magne N, Otto J, Thyss A and Schneider M: Combination of
cisplatin-doxorubicin-cyclophosphamide in adenocarcinoma of unknown
primary site: A phase II trial. Am J Clin Oncol. 24:372–375. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
van der Gaast A, Verweij J, Planting AS,
Hop WC and Stoter G: Simple prognostic model to predict survival in
patients with undifferentiated carcinoma of unknown primary site. J
Clin Oncol. 13:1720–1725. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kambhu SA, Kelsen DP, Fiore J, Niedzwiecki
D, Chapman D, Vinciguerra V and Rosenbluth R: Metastatic
adenocarcinoma of unknown primary site. Prognostic variables and
treatment results. Am J Clin Oncol. 13:55–60. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Seve P, Sawyer M, Hanson J, Broussolle C,
Dumontet C and Mackey JR: The influence of comorbidities, age, and
performance status on the prognosis and treatment of patients with
metastatic carcinoma of unknown primary site: A population-based
study. Cancer. 106:2058–2066. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pasterz R, Savaraj N and Burgess M:
Prognostic factors in metastatic carcinoma of unknown primary. J
Clin Oncol. 4:1652–1657. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lenzi R, Hess KR, Abbruzzese MC, Raber MN,
Ordoñez NG and Abbruzzese JL: Poorly differenciated carcinoma and
poorly differenciated adenocarcinoma of unknown origin: Favorable
subsets of patients with unknown-primary carcinoma? J Clin Oncol.
15:2056–2066. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Varadhachary GR, Talantov D, Raber MN,
Meng C, Hess KR, Jatkoe T, Lenzi R, Spigel DR, Wang Y, Greco FA, et
al: Molecular profiling of carcinoma of unknown primary and
correlation with clinical evaluation. J Clin Oncol. 26:4442–4448.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pentheroukadis G, Golfinopoulos V and
Pavlidis N: Swithing benchmarks in cancer of unknown primary: From
autopsy to microarray. Eur J Cancer. 43:2026–2036. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Fizazi K: Treatment of patients with
specific subsets of carcinoma of an unknown primary site. Ann
Oncol. 17:(Suppl 10). x177–x180. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Varadhachary GR and Greco FA: Overview of
patient management and future directions in unknown primary
carcinoma. Semin Oncol. 36:75–80. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Viale G and Mastropasqua MG: Diagnostic
and therapeutic management of carcinoma of unknown primary:
Histopathological and molecular diagnosis. Ann Oncol. 17:(Suppl
10). x163–x167. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
van de Wouw AJ, Jansen RL, Speel EJ and
Hillen HF: The unknown biology of the unknown primary tumour: A
literature review. Ann Oncol. 14:191–196. 2003. View Article : Google Scholar : PubMed/NCBI
|
